Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.4524
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 131445754400.0
- FreeCF/Share 1.665
- PFCF 13.9111
- PE 16.6801
- Debt/Assets 0.2946
- DivYield 0.0735
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Published: April 18, 2025 by: The Motley Fool
Sentiment: Positive
Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include household names such as Wegovy and Zepbound, two drugs whose sales are rapidly growing.
Read More
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Negative
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Read More
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
Read More
European pharma companies issue demands to stay in EU ahead of expected US tariffs
Published: April 15, 2025 by: Reuters
Sentiment: Negative
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations, French business newspaper Les Echos reported on Tuesday.
Read More
Pfizer Halts Obesity Pill Development Amid Safety Concerns
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
Read More
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields approaching 8%. Trade War Realities: Despite severe pessimism driven by historic tariff increases (highest since 1909), the actual economic impact might be significantly less dire, potentially avoiding recession altogether. Institutional strategies, such as pensions and risk parity funds, may soon trigger substantial stock-buying due to automatic rebalancing. This would provide strong support and fuel market rallies from oversold conditions.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug
Published: April 14, 2025 by: Schaeffers Research
Sentiment: Positive
Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 10.1% to trade at $24.42 today, and traded as high as $27.09 earlier in the session.
Read More
Pfizer discontinues development of weight loss pill
Published: April 14, 2025 by: Proactive Investors
Sentiment: Negative
Pfizer Inc (NYSE:PFE, ETR:PFE) announced it will discontinue the development of its experimental weight-loss pill, danuglipron, due to safety concerns. The company said on Monday that the decision comes after a clinical trial participant experienced a potential drug-induced liver injury, which resolved after stopping the medication.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Pfizer: Anticipating A Game-Changer Soon
Published: April 09, 2025 by: Seeking Alpha
Sentiment: Positive
I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to announce danuglipron updates soon, potentially boosting investor sentiment and stock performance. Pfizer's cost reduction programs and revenue growth targets for CY25 remain on track, with EPS projected to more than double.
Read More
5 Low Price-to-Book Stocks to Add to Your Portfolio in April
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, JD, PFE, STNE and ENS are some such stocks.
Read More
Pfizer: Best-In-Class Dividend Yield Together With Dirt Cheap Valuation
Published: April 09, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer's 7.5% dividend yield is safe due to revenue growth, cost efficiency, and a stronger balance sheet, making it a strong buy. Pfizer's innovation in R&D, including AI partnerships and new drug approvals, promises long-term market cap growth and a competitive edge. Defensive stocks like Pfizer are attractive amid market volatility, with the pharmaceutical sector being less vulnerable to economic cycles.
Read More
S&P 500: Pharma Giants Lead Decline as Tariff Threats Rattle Pfizer, Merck, Johnson & Johnson
Published: April 09, 2025 by: FXEmpire
Sentiment: Negative
Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.
Read More
5 Tariff Sell-Off Casualties That Now Pay 7% and Higher Dividends
Published: April 08, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Investors love dividend stocks, especially high-yield varieties, because they offer a significant income stream and have substantial total return potential.
Read More
Is Pfizer (PFE) Stock Undervalued Right Now?
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Read More
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JNJ & PFE expect their sales and profits to improve in 2025.
Read More
Is Pfizer Stock a Buy?
Published: April 03, 2025 by: The Motley Fool
Sentiment: Negative
Pfizer's (PFE 0.77%) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022.
Read More
2 Absurdly Cheap Stocks to Buy and Hold for Years
Published: April 03, 2025 by: The Motley Fool
Sentiment: Positive
Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.
Read More
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Read More
Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation
Published: April 02, 2025 by: Reuters
Sentiment: Negative
Institutional Shareholder Services is recommending Pfizer's investors to reject a management proposal on annual compensation for CEO Albert Bourla and other executives, the proxy adviser said on Wednesday.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Published: March 31, 2025 by: Fast Company
Sentiment: Negative
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Dr. Albert Bourla D.V.M., Ph.D.
- Employees 81000